Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Adverse reactions to biotechnological agents targeting IL-5]. | Rev Alerg Mex | 2025 | 41037709 | PubTator, text mining | PubMed |
| FCRLs and atypical transcriptional pattern in tumor infiltrating B cells from lung and renal cancer. | Front Immunol | 2025 | 40990023 | PubTator, text mining | PubMed |
| Multi-Criteria Decision Analysis of Biologics in Chronic Obstructive Pulmonary Disease. | Int J Chron Obstruct Pulmon Dis | 2025 | 40955382 | PubTator, text mining | PubMed |
| Review of the British Thoracic Society Winter Meeting 2024. | BMJ Open Respir Res | 2025 | 40953921 | PubTator, text mining | PubMed |
| Paradoxical Use of Benralizumab in Reactive Hypereosinophilia from Toxocariasis and Tuberculosis Co-Infection-Case Report and Literature Review. | Int J Mol Sci | 2025 | 40943043 | PubTator, text mining | PubMed |
| [Progress on biologic therapies for severe asthma]. | Zhonghua Jie He He Hu Xi Za Zhi | 2025 | 40925741 | PubTator, text mining | PubMed |
| Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab. | ACR Open Rheumatol | 2025 | 40886121 | PubTator, text mining | PubMed |
| Decoding Allergic Conjunctivitis: Latest Perspectives on Etiological Drivers and Immunopathological Mechanisms. | Clin Rev Allergy Immunol | 2025 | 40879847 | PubTator, text mining | PubMed |
| Biomarkers of type 2 inflammation as predictors of response to biologics for severe eosinophilic asthma. | ERJ Open Res | 2025 | 40874166 | PubTator, text mining | PubMed |
| Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review. | J Pers Med | 2025 | 40863432 | PubTator, text mining | PubMed |
| The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma. | Adv Respir Med | 2025 | 40862698 | PubTator, text mining | PubMed |
| Atypical mesenchyme in congenital pulmonary airways malformation: a promising new focus. | Respir Res | 2025 | 40859353 | PubTator, text mining | PubMed |
| Study on differentially expressed genes and pattern recognition receptors in osteoporosis based on bioinformatics analysis. | Sci Rep | 2025 | 40854963 | PubTator, text mining | PubMed |
| Mepolizumab-Related Blood Eosinophil Decreases Are Associated with Clinical Remission in Severe Asthmatic Patients: A Real-World Study. | Antibodies (Basel) | 2025 | 40843673 | PubTator, text mining | PubMed |
| Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium. | Lancet Reg Health Eur | 2025 | 40823190 | PubTator, text mining | PubMed |
| High sensitization to Rhizopus nigricans in children with allergic asthma in Southwest China: A microfluidic chip and proteomics study. | World Allergy Organ J | 2025 | 40822752 | PubTator, text mining | PubMed |
| Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma. | Allergy Asthma Clin Immunol | 2025 | 40804423 | PubTator, text mining | PubMed |
| Cell Type-Specific IL-5Rα Distribution and IL-5-Induced CCL11 Expression in Human Nasal Epithelium. | Allergy | 2025 | 40785590 | PubTator, text mining | PubMed |
| Benralizumab Depletes IL-5Rα-Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis. | Clin Transl Allergy | 2025 | 40781582 | PubTator, text mining | PubMed |
| Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. | Ann Rheum Dis | 2025 | 40781045 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers?page=7